Navigation Links
Selexis SA to Present at Biotech Showcase 2012
Date:1/5/2012

GENEVA, Switzerland, Jan. 5, 2012  /PRNewswire/ -- Selexis SA announced today the Company's president and CEO, Igor Fisch, Ph.D., will present at the Biotech Showcase 2012 Conference held in conjunction with the annual J.P. Morgan Healthcare Conference in San Francisco, CA.

Dr. Fisch will present, "Translating Drug Discovery into Clinical Success: A Growth Investment" to prospective investors and corporate partners on Monday, January 9 at 11:00 AM in the Stockton Room at the Park 55 Wyndham.   The presentation will cover existing commercial offerings, the expansion of the SUREtechnology Platform™ and new market opportunities in drug discovery, next generation biologics and difficult to express proteins. 

"Biotech Showcase is an ideal opportunity for us to highlight our innovations and our applications of the SUREtechnology Platform™ supporting the biopharmaceutical industry's drug discovery efforts," said Dr. Fisch.  "Using Selexis' platform from discovery through manufacturing helps improve chances of clinical success while reducing development timelines and costs."

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins.  The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials.  The Company anticipates three products manufactured from cell lines using t
'/>"/>

SOURCE Selexis SA
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Selexis Launches Biosimilar Cell Line Development Program
2. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
3. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
4. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
5. Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC
6. Selexis SA to Give Away Euro 25,000 SUREvariant Screening Service Project at BIO 2011
7. CSL Limited Signs Commercial License Agreement with Selexis SA
8. InterMune to Present at Canaccord Adams Conference
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
10. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
11. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 DTS Language Services, Inc . ... Portal for Life Science organizations who need document translations. ... matter of their documents in advance with a selection of ... of translations, often a critical factor in clinical and scientific ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: 6 p.m. ... Road, Warrington, Pa. , Details: The Hepatitis B ... a cure for hepatitis B and improving the quality of ... Ball on Friday, April 11 at Warrington Country Club in ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 EquitiesIQ, ... Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical ... serve the wound care market. , Free report download: ... restructured with a seasoned management team and Board, which ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... China, Feb. 12 /PRNewswire-Asia-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC ... company with its principal operations,in the People,s Republic of ... call at 9:00 a.m. Eastern on Tuesday, February 17, ... December 31, 2008 of,its fiscal year 2009. , ...
... Cord Blood America, Inc. (OTC Bulletin Board: CBAI), ... http://www.cordblood-america.com ) focused on bringing the life saving potential ... pleased to announce that between January 1, 2009, and ... approximately $1 million.The Company previously said in press releases ...
... (NYSE Alternext US: PTN) will announce its second quarter, ... 2009 before the open of the U.S. financial markets.Palatin ... webcast hosted by its executive management team on February ... of operations in greater detail and an update on ...
Cached Biology Technology:Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 2Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009 3Cord Blood Announces $1 Million Reduction in Long Term Debt 2Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009 2
(Date:7/9/2014)... Cholinergic inhibitors and N-methyl-D-aspartate receptor antagonists can ... fail to affect irreversible cognitive dysfunction and ... brain. Amyloid beta peptide (Aβ) vaccines reduced ... disease (AD) transgenic mouse model, and significantly ... Cao and his team, First Affiliated Hospital ...
(Date:7/9/2014)... copy of its DNA, a fundamental step in the life ... in the human body. While scientists have had an idea ... enzymes that unzip the double-stranded DNA and create "daughter" copiesthey ... works. , Now, researchers at Rockefeller University have built the ... "replication fork"the point where DNA is split down the middle ...
(Date:7/8/2014)... is an increased risk of severe perineal tearing during childbirth ... delivery, suggests a new study published today (9 July) in ... (BJOG). , This study, investigates among women who have had ... delivery in subsequent pregnancies and the recurrence of severe perineal ... childbirth and in some women the tear may be more ...
Breaking Biology News(10 mins):Rockefeller scientists first to reconstitute the DNA 'replication fork' 2Rockefeller scientists first to reconstitute the DNA 'replication fork' 3Rockefeller scientists first to reconstitute the DNA 'replication fork' 4Mode of delivery following a perineal tear and recurrence rate in subsequent pregnancies 2
... carry out one of the most remarkable forms of feeding ... extending its stomach out of its mouth and over the ... The prey tissue is partially digested externally before the soup-like ... , The researchers at Queen Mary, University of London and ...
... of breast cancer, termed estrogen receptor positive or ER+, ... each year. Research by scientists at the HudsonAlpha ... Birmingham Comprehensive Cancer Center aims to provide physicians a ... "Can we find something in the genome that correlates ...
... shape based on environment, fending off attackers or ... worked toward mimicking similar biological responses in non-living ... the medical arena. Now, researchers at ... biomimetic response using hydrogelsa material that constitutes most ...
Cached Biology News:Scientists uncover secrets of starfish's bizarre feeding mechanism 2HudsonAlpha and UAB researchers work to identify optimal treatments for ER+ breast cancer 2Light that moves and molds gels 2
Full-length cDNA clone CS0DJ013YG01 of T cells (Jurkat cell line) of Homo sapiens (human). [Source:Uniprot/SPTREMBL;Acc:Q86SZ3] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
...
...
All-in-one mix, removes primers and dNTPs from PCR product for following direct sequencing...
Biology Products: